Virinchi Limited seeks approval for Rs 30 crore warrants
Key highlights
- Virinchi proposes up to 2 crore warrants at Rs 15 each for maximum proceeds of Rs 30 crore.
- Viswanath Kompella is proposed to receive 1.5 crore warrants worth up to Rs 22.50 crore.
- Virinchi has allocated Rs 22.50 crore to working capital at Virinchi Health Care Private Limited.
- The filing shows fully diluted promoter ownership at 45.76%, compared with 39.46% before the issue.
powered by IRIS

In a November 10, 2026 proposal, Virinchi Limited seeks shareholder approval to raise up to Rs 30 crore through 2 crore preferential warrants priced at Rs 15 each, with Rs 22.50 crore allocated to the working capital of its subsidiary, Virinchi Health Care Private Limited. Promoter Viswanath Kompella is proposed to receive 1.5 crore warrants.
Know Virinchi inside out
Results, valuation, peers and who's buying, in one view.
What are shareholders being asked to approve?
Virinchi is asking shareholders to pass a special resolution authorising a preferential private-placement issue of up to 2 crore warrants at Rs 15 each, for maximum proceeds of Rs 30 crore. The board approved the proposal on November 10, 2026, subject to shareholder approval and any other required approvals.
Each warrant would be convertible into, or exchangeable for, one fully paid equity share with a face value of Rs 10. The Rs 15 warrant price includes a premium of Rs 5 per warrant, and the proposal is being made under the Companies Act, 2013 and the Securities and Exchange Board of India Issue of Capital and Disclosure Requirements Regulations.
The proposed allotment consists of 1.5 crore warrants for Viswanath Kompella, classified as a promoter, and 50 lakh warrants for IT Peer Technologies LLC, classified as public. At Rs 15 per warrant, Kompella’s maximum subscription would be Rs 22.50 crore, while IT Peer Technologies LLC’s would be Rs 7.50 crore.
How does Virinchi plan to use the Rs 30 crore?
Virinchi proposes to use Rs 22.50 crore, representing 75% of the maximum issue proceeds, for the working-capital needs of Virinchi Health Care Private Limited. The notice says the funds are intended to support the subsidiary’s operating activities and have a tentative utilisation timeline of 12 months from receipt.
Up to Rs 7.50 crore, or 25% of the issue proceeds, is earmarked for general corporate purposes, also within 12 months from receipt. Virinchi states that funds allocated to the stated objects must be used for those objects and cannot be added to the general-corporate-purpose allocation.
Virinchi says it does not need to appoint a monitoring agency because the proposed proceeds do not exceed Rs 100 crore under the cited regulation. Management estimates that proceeds from the convertible warrants would be received within 18 months of allotment and used for the disclosed objects within 12 months of receipt.
What are the warrant price and payment conditions?
Virinchi has fixed the proposed warrant price at Rs 15, above the disclosed regulatory floor price of Rs 14.52 per warrant and the Rs 14.92 per-share fair value cited from an independent valuer’s report. The relevant date for determining the floor price was November 9, 2026, because November 10, 2026 was a stock-exchange holiday, according to the notice.
The company says its equity shares are listed on BSE and NSE and are frequently traded. It used NSE for the pricing calculation because NSE had the higher trading volume during the prescribed preceding 90 trading days, and the Rs 14.52 floor price was based on the 90-trading-day volume weighted average price, or VWAP.
Proposed allottees must pay at least 25% of the issue price, or Rs 3.75 per warrant, at subscription and allotment. The remaining 75%, or Rs 11.25 per warrant, is payable on exercise, and holders can convert warrants in one or more tranches during the 18 months following allotment.
The conversion ratio is one equity share for every warrant, and warrants do not carry voting rights before conversion. Virinchi says resulting shares will be listed on BSE and NSE after allotment and will rank equally with existing shares for voting rights and dividends.
Got a follow-up? Ask IRIS
How could full conversion affect Virinchi’s ownership?
Virinchi’s shareholding table shows promoter ownership at 45.76% after full dilution, compared with 39.46% before the proposed issue, while public ownership is shown at 54.24%, down from 60.54%. The post-issue presentation assumes full conversion of the proposed 2 crore warrants as well as other outstanding convertible instruments disclosed in the notice.
As of the notice date, Virinchi reported 1.33 crore previously issued convertible warrants pending exercise and 58.90 lakh outstanding employee stock options, or ESOPs. These instruments help explain why the fully diluted share count in the post-issue table is 15.19 crore shares, compared with 11.27 crore pre-issue shares, rather than reflecting only the proposed 2 crore warrants.
From April 1, 2026 to the notice date, Virinchi allotted 39.10 lakh equity shares to 12 persons on conversion of earlier warrants. That group included 9.10 lakh shares allotted to IT Peer Technologies LLC and 8.50 lakh shares allotted to Vivo Bio Tech Limited, which the notice classifies as promoter group.
When could the warrants be allotted and converted?
Virinchi says the warrants must be allotted within 15 days of shareholders passing the special resolution, unless a regulatory approval or permission is pending. If approval is pending, allotment is to be completed within 15 days of that approval or within any further period allowed by the Securities and Exchange Board of India, stock exchanges or other authorities.
Holders would have 18 months from the allotment date to convert their warrants in one or more tranches. Following a conversion request and payment of the Rs 11.25 exercise amount per warrant, Virinchi says it will allot the corresponding equity shares within 15 days of exercise.
The warrants and the equity shares issued on conversion will be subject to the lock-in required under the applicable regulations. Virinchi also says it will file a statutory auditor’s certificate with stock exchanges confirming receipt of the warrant exercise amount under Regulation 169 of the Issue of Capital and Disclosure Requirements Regulations.
Conclusion
The proposal would allow Virinchi to raise up to Rs 30 crore, with Rs 22.50 crore designated for working capital at Virinchi Health Care Private Limited and up to Rs 7.50 crore for general corporate purposes. Promoter Viswanath Kompella’s proposed Rs 22.50 crore subscription accounts for 75% of the maximum issue, while the fully diluted ownership table shows promoter ownership rising to 45.76%.
The next disclosed event is shareholder consideration of the special resolution, after which the company targets allotment within 15 days, subject to regulatory permissions. Investors will also need to watch the pace of warrant exercise over the 18-month conversion period and management’s planned utilisation of funds within 12 months of receipt.


